BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/27/2022 1:00:18 PM | Browse: 322 | Download: 627
 |
Received |
|
2022-05-03 13:37 |
|
Peer-Review Started |
|
2022-05-03 13:38 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-16 02:32 |
|
Revised |
|
2022-06-29 00:40 |
|
Second Decision |
|
2022-08-22 03:07 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-25 20:38 |
|
Articles in Press |
|
2022-08-25 20:38 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-08-18 00:36 |
|
Typeset the Manuscript |
|
2022-09-14 08:27 |
|
Publish the Manuscript Online |
|
2022-09-27 13:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Su-Zhen Xu, Xiao-Chen Zhang, Qi Jiang, Ming Chen, Meng-Ye He and Peng Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peng Shen, PhD, Chief Doctor, Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. shenp@zju.edu.cn |
| Key Words |
Hepatoid adenocarcinoma; Lung cancer; Alpha-fetoprotein; Sorafenib; Case report |
| Core Tip |
Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare malignant tumor with poor prognosis and no standardized treatment strategy. To our knowledge, this is the first report to document a patient with unresectable alpha-fetoprotein-related HAL who benefited from single-agent sorafenib after multiline treatment. Sorafenib may be a viable option for inoperable, previously treated, advanced HAL. |
| Publish Date |
2022-09-27 13:00 |
| Citation |
Xu SZ, Zhang XC, Jiang Q, Chen M, He MY, Shen P. Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report. World J Clin Cases 2022; 10(28): 10236-10243 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i28/10236.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i28.10236 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
